Impel NeuroPharma Inc.

+0.26 (+2.79%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)227.35M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.66 Million
Adjusted EPS-$0.86
See more estimates
10-Day MA$10.06
50-Day MA$10.97
200-Day MAN/A
See more pivots

Impel NeuroPharma Inc. Stock, NASDAQ:IMPL

201 Elliott Avenue West, Suite 260, Seattle, Washington 98119
United States of America
Phone: +1.206.568.1466
Number of Employees: 63


Impel NeuroPharma, Inc. operates as clinical stage biotechnology firm that develops medical devices. It offers intranasal drug treatments for central nervous system (CNS) disorders. The firm product candidates includes TRUDHESA, INP105, and INP107. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.